Phreesia's own software line shrank while listed rivals grew.
Is it a good business? · 6 · What does its record show?
Cost cuts, not growth, made it profitable
Sales, $M
213.2
280.9
356.3
419.8
480.6
507.8
Jan 2022Jan 2023Jan 2024Jan 2025Jan 2026last 12 mo
Costs49.9¢ to 20.9¢sales and marketing per $1, fiscal 2022 to 2026
Software$219.5Msubscriptions, fiscal 2026
Own growthAbout 4.4%growth last quarter without AccessOne
Cutting staff and sales spending pulled it from heavy losses to a small profit.
Is it a good business? · 7 · How much room is there to grow?
Patients paid $556.6B of their own bills
$556.6BAmericans' own health bills, 2024
About $95.0Bpaid through doctors' offices
About 5%passing through Phreesia
It handled $4,873M of patient payments in fiscal 2026.
Is it a good business? · 8 · Who is in charge?
The co-founder still runs it
2005Chaim Indig co-founded it
About 5%owned by insiders
About 14%held by Pale Fire Capital
The bonus rides on sales and a profit figure that leaves out pay in shares.
The story right now · 9 · Why did drug advertising stall?
Washington pressed drug advertisers, and budgets shrank
September 2025Washington pressed drug advertisers
-29.8%a rival's drug-message sales
+8.9%Phreesia's advertising, latest quarter
Drug companies pay to reach patients just before they see a doctor. When regulators pressed them over advertising, the whole sector's budgets shrank.
The story right now · 10 · Where is the growth coming from?
A bought business hides a shrinking core
Phreesia buys AccessOnePatient payment plans.
Total sales rise 10.4%Mostly the purchase.
Software shrinks 1.9%Two quarters running.
Lending adds risk$419M of payment plans.
The market has priced the advertising stall, but not yet the software shrinking while rivals grow.
The story right now · 11 · What changed lately?
Sales rose 10.4% while software fell 1.9%
$129.5Mquarterly sales
+8.9%advertising
-1.9%software subscriptions
Mixed quarter
Most growth came from AccessOne, the bought lending business. Management gave no customer retention figures. The price is now far below its six-year average per dollar of sales.
The story right now · 12 · What is everyone arguing about?
Is the shrinking software chosen or forced?
Many investors think
Drug advertising is permanently smaller
We think
Right on ads; the shrinking software is not priced yet
Against us: management may have cut software prices to win more from payments and advertising. Subscription growth returning would prove it.
The price and our view · 13 · What is a share worth?
No single value here: profit after share pay is too thin
Forecasts show little profit after share pay, so a value built on earnings would rest on a guess. We judge it on the business events below instead.
The price and our view · 14 · How could we be wrong?
Drug ads, software rivals and share pay
Drug advertisingBiggest
29% of sales, sold a year at a time.
Software losing to rivalsShowing now
Two quarters of decline.
Lending riskWatch
About $419M of patient payment plans.
Chosen or forcedUnknown
No retention figures given.
New shares for staff take close to a third of the cash the business produces each year.
The price and our view · 15 · How will we know?
December shows whether software stops shrinking
Subscription revenue flat or up, advertising upGood sign
Shares issued to staff well below 3.4% a yearWe turn positive
Practices stop growing, purchases left outWe turn negative
DEC 202614
Third-quarter fiscal 2027 results, 14 December. Companies report every three months; each report is a test of the story.
Our view moves on these business events, not on a price line, since we put no single value on a share here.
The price and our view · 16 · So, what do we think?
It owns the waiting room, but the software shrinks
NeutralMedium conviction
Phreesia runs the check-in tablet at about one in six US doctor visits. The shares look cheap on cash, but advertising stalled, software is shrinking and growth came from a lending business it bought. Neutral.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
At the front desk the patient checks in on Phreesia's tablet or phone screen: insurance card captured, forms signed, the amount owed worked out and paid by card, a health questionnaire answered. Without it, the practice has a clipboard, a receptionist keying cards in by hand, and bills sent weeks later.
About 4,514 practices and health systems used it on average in fiscal 2026, handling about 180 million visits.
How it makes money
Three ways from one screen. Practices pay a yearly subscription, $219.5M in fiscal 2026. Card payments and patient payment plans earn fees, $121.5M. Drug companies pay to show patients health messages chosen from what they just answered, $139.7M. Every contract runs a year and has to be won again.
Growth and profit
What growth costs
Each dollar of sales now costs Phreesia far less to win than it did four years ago, which has pulled it from heavy losses to a small profit. Most of that came from cutting the sales force and staff rather than from growing, so it shows discipline more than a business that gets cheaper to run as it grows.
Its record
The numbers
Is it growing?Steady
Sales grew 13% over the twelve months to Jul 2026, about the same pace as the 14% in the year to Jan 2026.
Is it profitable?Thin
Operating margin is 2.5%, up from −38% in the year to Jan 2024.
How steady is it?Uneven
Yearly sales growth has ranged from +14% to +43% over the last 5 years.
Does it earn good returns?Low
Shareholders' money earned 3.1% a year, up from −35% in the year to Jan 2022.
Is it making cash?Strong
It turned 16% of sales into free cash, $80.7M over the last twelve months.
Is profit turning into cash?Real cash
Free cash flow was 7.7 times net income.
Are shares being diluted?Diluting
The share count rose 25% in 4.5 years, and pay in shares costs 12% of sales.
Why it wins
The evidence
Phreesia owns minutes that cannot be bought: the time a patient spends checking in. No advertising network can reach that screen without first winning thousands of practices one by one.
Because drug companies pay so well for the screen, Phreesia can charge practices less than a software-only rival. It earns about $106,467 a year from each client, and under half of that is the subscription. Clients grew 7% last year.
Who could beat it
The rivals in full
Each of the three buyers has somewhere else to go. Weave sells practices forms, scheduling and payments in one bundle and grew 15.5% in the June quarter; Waystar sells patient payments to hospitals and grew 18.1%. Phreesia's own software line shrank.
Each rival
Weave CommunicationsWEAV
The front-desk subscription itself - digital forms, appointment scheduling, reminders and card payments, bought as one bundle instead of Phreesia's.
The patient-payment half - electronic statements, card payments through a portal and flexible payment arrangements, sold to hospitals that already buy their claims software from it.
OptimizeRxOPRX
The drug-company budget for reaching a patient at the point of care, sold through record and prescribing systems rather than through a check-in tablet.
CareCredit (Synchrony Financial)SYF
The patient payment plan AccessOne sells, from a lender with a far larger book and provider agreements that are mostly non-exclusive.
How big it could get
The market and who has signed
The market
Americans paid $556.6B of their own health bills in 2024, up 5.9%. Phreesia estimates about $95.0B of that passes through doctors' offices like the ones it serves.
It handled $4,873M of patient payments in fiscal 2026, about 5% of that pool.
Who runs it
Leaders, pay and the cash
Who runs it
Chaim Indig co-founded Phreesia in 2005 and still runs it; Balaji Gandhi has run the money since 2023. Insiders own about 5%, and an outside fund, Pale Fire Capital, holds about 14%. The yearly bonus rides on sales and a profit figure that leaves out pay in shares; the long-term shares pay only if the stock beats most of the market. Nothing pays for shrinking the share count, and the company has bought none back.
What they did with the money
It bought AccessOne for about $163.7M and has already repaid over $23M of debt in one quarter, leaving cash slightly above debt. In May it cut about 220 positions. The share count rose 3.43% in a year, as staff were paid in stock.
The last report
The latest report
Phreesia's sales rose 10.4% to $129.5M while its software subscription fell 1.9%
What it did to the thesis Mixed quarter
It sharpened the central worry: the software line shrank again while the bought lending business supplied the growth. Management's explanation went unproven when it declined to give retention figures. The view stays Neutral, cheap on cash but with flat underlying sales.
The report
In the quarter to 31 July 2026 sales rose 10.4% to $129.5M, but most of the growth came from AccessOne, the patient-lending business bought in November. Advertising grew 8.9%.
The software subscription fell 1.9%, its second quarterly decline. Management calls it deliberate price restraint; the quarterly report blames one-time fee adjustments. Asked for client-retention figures that would settle it, management gave none. The year's forecasts were held.
What's happening now
The background
What stands in the way is the revenue. Washington has pressed drug companies on their advertising since September 2025, and budgets have been cut. The next results, due 14 December, show whether the software line stops shrinking and advertising keeps growing into the second half.
Where we disagree
Both sides in full
The market
Analysts still rate it a buy, while the price says drug advertising is permanently smaller and the growth story is over.
We believe
The market has the advertising roughly right, and has not yet reacted to the software line shrinking while listed rivals grow.
The argument
The guidance cut everyone watched was the sector's: OptimizeRx, a listed rival selling drug messages through doctors' record systems, saw sales fall 29.8% in the June quarter. The fact underneath is Phreesia's own, and it sits in the revenue table rather than the headline.
The case against us: management may be right that it cut software prices to win more from payments and advertising. Subscription growth returning would prove it.
What it's worth
How we value it
No fair value: the analysts' forecasts show little operating profit after stock pay, so a value built on earnings would rest on a guess; the view reads the price against the business itself.
What could go wrong
Every risk
The risks
Drug advertising under pressure
Federal action has already cut drug companies' marketing budgets, and advertising is 29% of sales, sold one year at a time.
Software losing to rivals
The subscription line has declined two quarters running while two listed rivals grew over 15%.
Staff paid in shares
Share issuance takes close to a third of the cash the business produces each year.
Lending risk
AccessOne carries about $419M of patient payment plans; Phreesia can recover losses from the practices, which puts client goodwill at stake.
What we still do not know
Whether the software decline is chosen or forced. Management has given no retention or renewal figures that would tell them apart.
How profitable each of the three lines is. Phreesia reports one segment, so no separate margin is published.
What changes our view
Every route to a new view
Every route to a new view
→ Attractive
Shares issued to staff fall clearly below about 3.4% of the company a year, counted in shares, not dollars. Subscription revenue grows across fiscal 2028 instead of shrinking again, with advertising revenue growing from a year earlier.
→ Unattractive
The number of practices using it stops growing once those gained by acquisition are left out. AccessOne's outstanding patient payment plans shrink or losses appear against them, or the adjusted profit forecast is cut.
The next test
It supports the case if
Subscription revenue flat or up year over year, network solutions up year over year, and both the $510-520M revenue and $125-135M adjusted EBITDA guides held or raised.
It pressures the case if
Subscription revenue declines a third consecutive quarter without one-time items to explain it, network solutions falls year over year, or either guide is cut.
We would also be wrong if
Advertising revenue falls from a year earlier for two quarters running.
The verdict
Scores and how we weighed it
The scores
Growth
2 of 4
Business quality
3 of 4
Financial position
3 of 4
Execution record
3 of 4
Per share capture
2 of 4
Potential
2 of 4
Risk profile
3 of 4
Valuation
3 of 4
Evidence quality
3 of 4
How we weighed it
ValueMixed
No fair value is drawn: the forecasts show little profit after stock pay, so the price is read against the business itself.
BusinessNegative
A mixed business: advertising stalled and the software line shrinks.
GrowthNegative
Growth now comes from a bought lending business while the core line shrinks.
RisksNegative
Federal action cut drug marketing, rivals are taking software customers, share pay is large and lending adds credit risk.
RivalsMixed
No filed rival compares directly, so the price is judged on its own.
The groupMixed
It sits in none of our ranked groups; drug marketing budgets move it.
Latest newsNegative
The last report sharpened the worry: software shrank again and retention figures were withheld.